The DOI matches its Crossref record.
In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts.
Open accessAbstract
Recently, it has been reported that the protein kinase C (PKC) beta isoform plays a critical role in the development of hypertrophy and heart failure. The purpose of the present study was to clarify the mechanism by which activation of PKCbeta led to depressed cardiac function. Thus, we used a PKCbeta2 overexpressing mouse, an animal model of heart failure, to examine mechanical properties and Ca2+ signals of isolated left ventricular cardiomyocytes. The percentage of shortening, rate of shortening, and rate of relengthening of cardiomyocytes were markedly reduced in PKCbeta2 overexpression mice compared to wild-type control mice, although the baseline level and amplitude of Ca2+ signals were similar. These findings suggested a decreased myofilament responsiveness to Ca2+ in transgenic hearts. Therefore, the incorporation of [32P] inorganic phosphate into cardiac myofibrillar proteins was studied in Langendorff-perfused hearts. There was a significant increase in the degree of phosphorylation of troponin I in PKCbeta2-overexpressing transgenic mice. The depressed cardiomyocyte function improved after the superfusion of a PKCbeta selective inhibitor. These findings indicate that in vivo PKCbeta2-mediated phosphorylation of troponin I may decrease myofilament Ca2+ responsiveness, and thus causes cardiomyocyte dysfunction. Since chronic and excess activation of PKCbeta2 plays a direct and contributory role in the progression of cardiac dysfunction, the PKCbeta selective inhibitor may provide a new therapeutic modality in the setting of heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cytoplasmic Signaling Pathways That Regulate Cardiac Hypertrophy
Molkentin, J. D., & Dorn II, G. W. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.391 · Cited by 689
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
The role of protein kinase C activation and the vascular complications of diabetes
DASEVCIMEN, N., & KING, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.016 · Cited by 494
Self-citationIdentification of PKC-isoform-specific biological actions using pharmacological approaches
Way, K. J., Chou, E., & King, G. L. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01468-1 · Cited by 435
Self-citationRegulation of cardiac contractile function by troponin I phosphorylation
LAYLAND, J., SOLARO, R., & SHAH, A. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.022 · Cited by 385
Calcium Signaling in Cardiac Myocytes
Fearnley, C. J., Roderick, H. L., & Bootman, M. D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004242 · Cited by 339
Protein kinase C and the development of diabetic vascular complications
Way, K. J., Katai, N., & King, G. L. (2001) · Diabetic Medicine · doi:10.1046/j.0742-3071.2001.00638.x · Cited by 313
Self-citationVANDERVELDEN, J., PAPP, Z., ZAREMBA, R., BOONTJE, N., DEJONG, J., OWEN, V, BURTON, P., GOLDMANN, P., JAQUET, K., & STIENEN, G. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00606-5 · Cited by 301
Oxidative Stress and Sarcomeric Proteins
Steinberg, S. F. (2013) · Circulation Research · doi:10.1161/circresaha.111.300496 · Cited by 195
Developing the next generation of cardiac markers: Disease-induced modifications of troponin I
McDonough, J. L., & Van Eyk, J. E. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.07.001 · Cited by 62
de Tombe, P. P., & Solaro, R. J. (2000) · Annals of Biomedical Engineering · doi:10.1114/1.1312189 · Cited by 61
Metadata
- Authors
- Takeishi, Y., Chu, G., Kirkpatrick, D. M., Li, Z., Wakasaki, H., Kranias, E. G., King, G. L., & Walsh, R. A.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-07-01
- Volume
- 102
- Issue
- 1
- Pages
- 72-78
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2071187274
- Cited by
- 179
- References
- 0
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.